Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 290
Selected: 0
NCT IDTitle
NCT03850691Radiation and Combination Immunotherapy for Melanoma
NCT01666080Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
NCT00400803Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
NCT00775931Allogeneic Transplantation For Severe Osteopetrosis
NCT01451502Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
NCT01343368Preservation of Ovarian Function After Hematopoietic Cell Transplant
NCT00620295Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
NCT02582775MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
NCT00455312Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
NCT06412497MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
NCT03314974Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT04003805Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users
NCT01526603High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
NCT01171469Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
NCT05114837Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL
NCT00293293Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
NCT02179359Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
NCT02991898Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
NCT00167219Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
NCT01464359T-Cell Depleted Double UCB for Refractory AML
NCT02118285Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT01207076AHN-12 Biodistribution in Advanced Leukemia
NCT01043640Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
NCT00095160Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors
NCT00356941Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
NCT00769990Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
NCT00623077MT2004-30: Tomotherapy for Solid Tumors
NCT00630565Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
NCT03297463Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
NCT00617929Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
NCT00652899Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
NCT00303667Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
NCT02118311Treg Cells for AGVHD in Non-myeloablative UCB Transplant
NCT00345865Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
NCT00818649Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT02845414Study of CD133KDEL Toxin in the Treatment for Solid Tumors
NCT00176878Stem Cell Transplant for Bone Marrow Failure Syndromes
NCT00855114Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
NCT03557749Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
NCT04714372FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
NCT00643240Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
NCT02395822MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
NCT03934840CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
NCT05735717MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
NCT03294304BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
NCT01652092Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
NCT00625092Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies
NCT06544811American Indian Smokefree Native RCT
NCT01106950Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
NCT02765997StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies